A Study of Itolizumab (EQ001) to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity in Uncontrolled Asthma
Status:
Recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
This is a multi-center study to evaluate the safety, tolerability, PK, PD, and clinical
activity of itolizumab (EQ001) in subjects with moderate-to-severe asthma.